Objective To estimate the incidence of hepatitis C virus (HCV) seroconversion and the risk of severe fibrosis/cirrhosis in HCV seroconverters among persons with human immunodeficiency virus (HIV) infection. Methods We analysed data on 4059 persons with HIV enrolled in a cohort study in Italy. Results Incidence rate of seroconversion was 0.6/100 person-years overall, and drug users and men-who-have-sex-with-men were at highest risk. The cumulative risk of progression to severe fibrosis/cirrhosis was 30% by 10 years after seroconversion. Conclusions New HCV infections have a rapidly progressive course in this population. Persons with HIV and HCV superinfection should be prioritized for treatment with anti-HCV direct-acting antivirals.
Incidence and progression to cirrhosis of new hepatitis C virus infections in persons living with human immunodeficiency virus / Puoti, M.; Lorenzini, P.; Cozzi-Lepri, A.; Gori, A.; Mastroianni, C.; Rizzardini, G.; Mazzarello, G.; Antinori, A.; d'Arminio Monforte, A.; Girardi, E.; the Icona Foundation Study, Group. - In: CLINICAL MICROBIOLOGY AND INFECTION. - ISSN 1198-743X. - STAMPA. - 23:4(2017), pp. 267.e1-267.e4. [10.1016/j.cmi.2016.12.003]
Incidence and progression to cirrhosis of new hepatitis C virus infections in persons living with human immunodeficiency virus
Mastroianni, C.;
2017
Abstract
Objective To estimate the incidence of hepatitis C virus (HCV) seroconversion and the risk of severe fibrosis/cirrhosis in HCV seroconverters among persons with human immunodeficiency virus (HIV) infection. Methods We analysed data on 4059 persons with HIV enrolled in a cohort study in Italy. Results Incidence rate of seroconversion was 0.6/100 person-years overall, and drug users and men-who-have-sex-with-men were at highest risk. The cumulative risk of progression to severe fibrosis/cirrhosis was 30% by 10 years after seroconversion. Conclusions New HCV infections have a rapidly progressive course in this population. Persons with HIV and HCV superinfection should be prioritized for treatment with anti-HCV direct-acting antivirals.| File | Dimensione | Formato | |
|---|---|---|---|
|
Puoti_Incidence_2017.pdf
solo gestori archivio
Note: Articolo principale
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
246.44 kB
Formato
Adobe PDF
|
246.44 kB | Adobe PDF | Contatta l'autore |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
